This session will provide delegates with an overview of the Centre for Excellence in Regulatory Science and Innovation (CERSI) in Pharmacogenomics project, which has a focus on the implementation of pharmacogenomics into the NHS. Pharmacogenomic testing guidelines for Carbamazepine and Clozapine have been developed, with the aims of improving patient outcomes and reducing safety issues. The session will cover the research evidence base for the guidelines, clinical pathways and health economic analysis of likely cost savings. The role of psychiatrists as key clinicians in the implementation of the guidelines will be discussed. Patient and carer perspectives on the potential benefits of pharmacogenomics testing will be highlighted.
Learning objectives
In this session the research evidence base that underpins the pharmacogenomic guidelines will be outlined. You will understand the key recommendations made in the Carbamazepine and Clozapine pharmacogenomic testing guidelines, and will be aware of the role of psychiatrists in implementing the guidelines. The benefits to patients of implementing the pharmacogenomic guidelines, in terms of improved outcomes and reduced adverse events, will be explored.
Speakers
Chair: Professor Regi Alexander, Hertfordshire Partnership University NHS Foundation Trust, Little Plumstead
Professor Sir Munir Pirmohamed, David Weatherall Chair of Medicine and NHS Chair of Pharmacogenetics, Liverpool
Professor Elvira Bramon, University College London, London
Dr David Crepaz-Keay, The Mental Health Foundation, London
Funding
RCPsych International Congress is financially supported by the purchase of exhibition stand packages. A full list of confirmed exhibitors can be found here: Exhibiting Organisations at International Congress 2026
Availability
This webinar is part of the Congress webinar 2026 package. If you attended all four days of Congress, you will have access to these as part of your Congress package. Otherwise the Congress webinar 2026 package can be purchased below.
